Exchange: NASDAQ·Updated 07:59 PM EDT
SLS logo

SLSSELLAS Life Sciences Group Inc

$8.05
$0.29
(3.74%)
Today
Closed $8.05
$0.0508
(0.63%)
After Hours
EarningsAug 11
Mkt Cap$1.44B
Vol14.75M
News
all
press releases
All Eyes On SLS Stock Ahead Of Annual Shareholder Meet – What’s On The Agenda?
Shareholders are set to vote on five proposals, including one to increase the number of shares available under the 2023 Equity Incentive Plan.
Stocktwits
News Placeholder
More News
News Placeholder
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute
Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.
Stocktwits
News Placeholder
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers
Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.
Stocktwits
News Placeholder
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout
CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."
Stocktwits
News Placeholder
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS
Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.
Stocktwits
News Placeholder
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms
Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ahead of the Regal data release.
Stocktwits
News Placeholder
SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout
The company plans to move quickly toward a pre-BLA meeting with the FDA and a potential filing if the REGAL trial reports positive results.
Stocktwits
News Placeholder
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst
Retail speculation intensified as short interest in SLS climbed to a record high of 30.7% ahead of the final Regal catalyst.
Stocktwits
News Placeholder
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS
Beyond leukemia, Sellas said GPS could potentially expand into up to 20 different tumor types.
Stocktwits
News Placeholder
Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs?
Arm Holdings surged more than 15%, while Sellas Life Sciences rallied by over 18% and eBay climbed up 4% at close.
Stocktwits
<
1
2
...
>